Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PureTech Health ( (GB:PRTC) ) has provided an announcement.
PureTech Health announced its total voting rights and share capital as of August 31, 2025, with 257,927,489 ordinary shares issued and 16,243,451 held in treasury, resulting in 241,684,038 total voting rights. This disclosure is significant for shareholders who need to assess their interests under the FCA’s rules, impacting their investment decisions and the company’s transparency in the market.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £130.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on GB:PRTC Stock
According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.
PureTech Health’s overall stock score reflects a mixed financial performance with strong liquidity but challenges in profitability. Technical indicators suggest bearish momentum, while the valuation appears attractive. The earnings call provided a cautiously optimistic outlook, though management changes and funding uncertainties pose risks.
To see Spark’s full report on GB:PRTC stock, click here.
More about PureTech Health
PureTech Health is a biotherapeutics company that operates with a hub-and-spoke model, focusing on transforming scientific innovation into value through a capital-efficient R&D approach. The company targets opportunities with validated pharmacology to address significant patient needs, resulting in the development of multiple therapeutic candidates, including three FDA-approved treatments. PureTech Health aims to accelerate the path of these assets to patients while creating value for shareholders.
Average Trading Volume: 374,183
Technical Sentiment Signal: Strong Sell
Current Market Cap: £298.3M
See more insights into PRTC stock on TipRanks’ Stock Analysis page.